<ul>
<li>如果你在想辉瑞是否正在悄然转变为一个价值投资机会，而不仅仅是一个防御性的医疗保健名称，你并不孤单，最近的数据给我们提供了很多分析的空间。</li>
<li>尽管经历了艰难的几年，辉瑞的股价在三年内仍下跌约 42.8%，五年内下跌 13.4%，但它已经开始稳定。过去一周上涨了 0.4%，过去一个月上涨了 1.1%，过去一年上涨了 9.1%，尽管年初至今仍下跌 3.0%。</li>
<li>最近的新闻集中在辉瑞重塑其疫情后的身份。公司在非 COVID 产品线方面进行了大量投资，并追求战略交易和合作伙伴关系，以多样化未来的收入。同时，投资者正在权衡关于专利悬崖、药品定价改革以及新疗法替代成熟重磅药物所需的漫长过程的持续讨论。</li>
<li>在我们的估值框架中，辉瑞在低估检查中得分为 5/6，给出了一个坚实的估值分数 5，这表明市场可能仍在低估故事的某些部分。接下来，我们将分析标准的估值方法，然后以更细致的方式思考这只股票的真实价值。</li>
</ul>
<p>了解为什么辉瑞过去一年 9.1% 的回报落后于同行。</p>
<h3>方法 1：辉瑞折现现金流（DCF）分析</h3>
<p>折现现金流（DCF）模型通过预测未来现金流并将其折现回现在来估算公司的当前价值。对于辉瑞，该模型以过去 12 个月的自由现金流约 99 亿美元为起点，然后结合分析师的预测和未来十年的长期外推。</p>
<p>分析师预计辉瑞将在未来几年内将自由现金流提升至中等十几亿美元，预计到 2026 年约为 193 亿美元，到 2035 年逐渐降至约 165 亿美元，随着增长的正常化。Simply Wall St 使用两阶段自由现金流到股权的框架，第一阶段依赖于分析师的估计，第二阶段假设增长放缓。</p>
<p>当这些未来现金流被折现回现值时，该模型得出的内在价值约为每股 62.40 美元。与当前市场价格相比，这意味着大约 58.7% 的折扣，表明市场价格显著低于该模型对辉瑞现金生成潜力的估计。</p>
<p><strong>结果：被低估</strong></p>
<p>我们的折现现金流（DCF）分析表明辉瑞被低估了 58.7%。将其添加到你的观察列表或投资组合中，或发现基于现金流的 904 只被低估股票。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/dcf?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1706" height="760" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/dcf"/></p>
<p>截至 2025 年 12 月的辉瑞折现现金流</p>
<p>前往我们公司报告的估值部分，了解我们如何得出辉瑞的公允价值的更多细节。</p>
<h3>方法 2：辉瑞市盈率</h3>
<p>对于像辉瑞这样成熟且盈利的企业，市盈率（PE）是衡量投资者是否为每一美元的收益支付合理价格的实用方法。一般来说，具有更强增长前景和较低感知风险的公司往往能获得更高的市盈率，而增长缓慢或不确定性较高的公司通常会指向较低、更保守的倍数。</p>
<p>辉瑞目前的市盈率约为 15.0 倍，低于大约 19.9 倍的制药行业整体平均水平，也低于约 17.5 倍的同行平均水平。从表面上看，这一折扣表明市场对辉瑞的收益轨迹和疫情后的重置仍持谨慎态度。</p>
<p>Simply Wall St 的公允比率框架进一步估算辉瑞应该交易的市盈率，考虑到其收益增长前景、利润率、规模、行业特征和风险因素。对于辉瑞，该公允比率为更高的 26.2 倍，这表明一旦考虑到这些基本面，股票似乎应当获得比同行和整个行业更高的倍数。将公允比率与当前的 15.0 倍市盈率进行比较，突显出这只股票在这一基础上看起来被低估。</p>
<p><strong>结果：被低估</strong></p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/pe-multiple-vs-industry?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1640" height="650" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/pe-multiple-vs-industry"/></p>
<p>截至 2025 年 12 月的 NYSE:PFE 市盈率</p>
<p>市盈率讲述了一个故事，但如果真正的机会在其他地方呢？发现 1447 家公司，内部人士正在大举押注于爆炸性增长。</p>
<h3>提升你的决策能力：选择你的辉瑞叙事</h3>
<p>早些时候我们提到，有一种更好的方式来理解估值，因此让我们向你介绍叙事，这是一种将你对辉瑞未来的看法与收入、收益、利润率和公允价值估计等具体数字联系起来的简单方法。叙事是你假设背后的故事，将关于产品线、专利悬崖或成本削减的想法转化为结构化的预测，然后转化为公允价值，你可以直接与今天的股价进行比较，以决定是买入、持有还是卖出。在 Simply Wall St 上的叙事，面向数百万投资者，通过社区页面提供，旨在易于使用，并随着新数据、新闻和收益的发布动态更新，以便你的故事与现实保持同步。例如，一个辉瑞叙事可能假设基于更强的利润率和成功的肥胖及肿瘤扩展，公允价值约为每股 35.77 美元，而一个更谨慎的叙事可能会看到公允价值接近 24.00 美元，反映出更严格的定价、较慢的增长和执行风险。</p>
<p>然而，对于辉瑞，我们将为你提供两个领先辉瑞叙事的预览：</p>
<p><strong>🐂 辉瑞牛市案例</strong></p>
<p>在这个看涨叙事中，公允价值估计为每股 29.08 美元。</p>
<p>在最后收盘价为 25.80 美元的情况下，这意味着辉瑞的交易价格大约低于该公允价值 11.3%。</p>
<p>在这种情况下，收入增长模型约为每年-2.9%。</p>
<ul>
<li>假设肥胖症、肿瘤学和其他晚期创新疗法支持辉瑞的重新评级，并在专利到期的情况下支撑长期盈利韧性。</li>
<li>依靠数字化、新兴市场扩张和有针对性的交易来推动利润改善，并减少 COVID 时代的波动性。</li>
<li>与看涨分析师的观点大致一致，他们认为美国整体定价担忧的缓解和管道执行是多重扩张的催化剂。</li>
</ul>
<p><strong>🐻 辉瑞熊市案例</strong></p>
<p>在这个更谨慎的叙述中，公允价值定为每股 24.00 美元。</p>
<p>目前股价为 25.80 美元，这意味着辉瑞的交易价格约高出这一悲观公允价值 7.5%。</p>
<p>在这种情况下，收入增长模型约为每年-4.2%。</p>
<ul>
<li>强调全球药品价格压力、美国政策改革和关键产品的专利悬崖是可能侵蚀收入和压缩利润的逆风。</li>
<li>质疑新的研发资产和收购是否能及时到位，并且规模足够大，以抵消老牌畅销药的侵蚀。</li>
<li>认为今天的股价接近公允价值或略显高估，如果定价改革和竞争压力在悲观预期下展开，潜在上行空间有限。</li>
</ul>
<p>你认为辉瑞的故事还有更多内容吗？前往我们的社区看看其他人怎么说！</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1510" height="1044" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/quote-price"/></p>
<p>纽约证券交易所:PFE 1 年股票价格走势图</p>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>用于国防和灾难的移动基础设施</p>
<p>下一波机器人技术不是类人型的，而是完全自主的塔楼，能够在 30 分钟内提供 5G、ISR 和雷达服务，覆盖任何地方。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

辉瑞

<p>辉瑞可能正在从防御性股票转变为疫情后价值投资机会。尽管过去股价下跌，但最近的涨幅和在非新冠领域的战略投资表明公司正在重组。使用折现现金流（DCF）和市盈率（PE）进行的估值分析显示，辉瑞被低估，与内在价值和行业平均水平相比存在显著折扣</p>

<ul>
<li>If you are wondering whether Pfizer is quietly setting up to be a value play rather than just a defensive healthcare name, you are not alone, and the recent numbers give us plenty to unpack.</li>
<li>Despite a tough few years, with the stock still down about 42.8% over three years and 13.4% over five, it has started to stabilize. It has posted a modest 0.4% gain over the last week, 1.1% over the last month, and a 9.1% rise over the past year, even though it remains down 3.0% year to date.</li>
<li>Recent news has centered on Pfizer reshaping its post pandemic identity. The company has been investing heavily in its non COVID pipeline and pursuing strategic deals and partnerships to diversify future revenue. At the same time, investors are weighing ongoing debates around patent cliffs, drug pricing reforms, and the long runway needed for new therapies to replace maturing blockbusters.</li>
<li>On our valuation framework, Pfizer scores a 5/6 on undervaluation checks, giving it a solid valuation score of 5 that suggests the market may still be underestimating parts of the story. Next, we will unpack the standard valuation approaches before finishing with a more nuanced way to think about what this stock is really worth.</li>
</ul>
<div class="lb-trans"><ul>
<li>如果你在想辉瑞是否正在悄然转变为一个价值投资机会，而不仅仅是一个防御性的医疗保健名称，你并不孤单，最近的数据给我们提供了很多分析的空间。</li>
<li>尽管经历了艰难的几年，辉瑞的股价在三年内仍下跌约 42.8%，五年内下跌 13.4%，但它已经开始稳定。过去一周上涨了 0.4%，过去一个月上涨了 1.1%，过去一年上涨了 9.1%，尽管年初至今仍下跌 3.0%。</li>
<li>最近的新闻集中在辉瑞重塑其疫情后的身份。公司在非 COVID 产品线方面进行了大量投资，并追求战略交易和合作伙伴关系，以多样化未来的收入。同时，投资者正在权衡关于专利悬崖、药品定价改革以及新疗法替代成熟重磅药物所需的漫长过程的持续讨论。</li>
<li>在我们的估值框架中，辉瑞在低估检查中得分为 5/6，给出了一个坚实的估值分数 5，这表明市场可能仍在低估故事的某些部分。接下来，我们将分析标准的估值方法，然后以更细致的方式思考这只股票的真实价值。</li>
</ul>
</div><p>Find out why Pfizer's 9.1% return over the last year is lagging behind its peers.</p>
<div class="lb-trans"><p>了解为什么辉瑞过去一年 9.1% 的回报落后于同行。</p>
</div><h3>Approach 1: Pfizer Discounted Cash Flow (DCF) Analysis</h3>
<div class="lb-trans"><h3>方法 1：辉瑞折现现金流（DCF）分析</h3>
</div><p>A Discounted Cash Flow (DCF) model estimates what a company is worth today by projecting future cash flows and discounting them back to the present. For Pfizer, the model starts with last twelve month Free Cash Flow of about $9.9 billion, then layers in analyst forecasts and longer term extrapolations for the next decade.</p>
<div class="lb-trans"><p>折现现金流（DCF）模型通过预测未来现金流并将其折现回现在来估算公司的当前价值。对于辉瑞，该模型以过去 12 个月的自由现金流约 99 亿美元为起点，然后结合分析师的预测和未来十年的长期外推。</p>
</div><p>Analysts expect Pfizer to lift Free Cash Flow into the mid teens over the coming years, with projections around $19.3 billion in 2026 and tapering toward roughly $16.5 billion by 2035 as growth normalizes. Simply Wall St uses a 2 Stage Free Cash Flow to Equity framework, where the first stage relies on analyst estimates and the second stage assumes more modest, slowing growth.</p>
<div class="lb-trans"><p>分析师预计辉瑞将在未来几年内将自由现金流提升至中等十几亿美元，预计到 2026 年约为 193 亿美元，到 2035 年逐渐降至约 165 亿美元，随着增长的正常化。Simply Wall St 使用两阶段自由现金流到股权的框架，第一阶段依赖于分析师的估计，第二阶段假设增长放缓。</p>
</div><p>When those future cash flows are discounted back, the model arrives at an intrinsic value of about $62.40 per share. Compared with the current market price, this implies roughly a 58.7% discount, indicating that the market price is significantly below this model’s estimate of Pfizer’s cash generation potential.</p>
<div class="lb-trans"><p>当这些未来现金流被折现回现值时，该模型得出的内在价值约为每股 62.40 美元。与当前市场价格相比，这意味着大约 58.7% 的折扣，表明市场价格显著低于该模型对辉瑞现金生成潜力的估计。</p>
</div><p><strong>Result: UNDERVALUED</strong></p>
<div class="lb-trans"><p><strong>结果：被低估</strong></p>
</div><p>Our Discounted Cash Flow (DCF) analysis suggests Pfizer is undervalued by 58.7%. Track this in your watchlist or portfolio, or discover 904 more undervalued stocks based on cash flows.</p>
<div class="lb-trans"><p>我们的折现现金流（DCF）分析表明辉瑞被低估了 58.7%。将其添加到你的观察列表或投资组合中，或发现基于现金流的 904 只被低估股票。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/dcf" alt="" original-src="https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/dcf"/></p>
<p>PFE Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的辉瑞折现现金流</p>
</div><p>Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Pfizer.</p>
<div class="lb-trans"><p>前往我们公司报告的估值部分，了解我们如何得出辉瑞的公允价值的更多细节。</p>
</div><h3>Approach 2: Pfizer Price vs Earnings</h3>
<div class="lb-trans"><h3>方法 2：辉瑞市盈率</h3>
</div><p>For a mature, profitable business like Pfizer, the Price to Earnings, or PE, ratio is a practical way to gauge whether investors are paying a reasonable price for each dollar of earnings. In general, companies with stronger growth prospects and lower perceived risk tend to justify a higher PE, while slower growth or higher uncertainty usually points to a lower, more conservative multiple.</p>
<div class="lb-trans"><p>对于像辉瑞这样成熟且盈利的企业，市盈率（PE）是衡量投资者是否为每一美元的收益支付合理价格的实用方法。一般来说，具有更强增长前景和较低感知风险的公司往往能获得更高的市盈率，而增长缓慢或不确定性较高的公司通常会指向较低、更保守的倍数。</p>
</div><p>Pfizer currently trades on a PE of about 15.0x, which sits below the broader Pharmaceuticals industry average of roughly 19.9x and also below the peer group average of about 17.5x. On the surface, that discount suggests the market is still cautious about Pfizer’s earnings trajectory and post pandemic reset.</p>
<div class="lb-trans"><p>辉瑞目前的市盈率约为 15.0 倍，低于大约 19.9 倍的制药行业整体平均水平，也低于约 17.5 倍的同行平均水平。从表面上看，这一折扣表明市场对辉瑞的收益轨迹和疫情后的重置仍持谨慎态度。</p>
</div><p>Simply Wall St’s Fair Ratio framework goes a step further by estimating what PE Pfizer should trade on, given its earnings growth outlook, profit margins, size, industry profile, and risk factors. For Pfizer, that Fair Ratio is a much higher 26.2x, which indicates that, once these fundamentals are accounted for, the shares appear to warrant a richer multiple than both peers and the sector overall. Comparing the Fair Ratio with the current 15.0x PE highlights a stock that looks undervalued on this basis.</p>
<div class="lb-trans"><p>Simply Wall St 的公允比率框架进一步估算辉瑞应该交易的市盈率，考虑到其收益增长前景、利润率、规模、行业特征和风险因素。对于辉瑞，该公允比率为更高的 26.2 倍，这表明一旦考虑到这些基本面，股票似乎应当获得比同行和整个行业更高的倍数。将公允比率与当前的 15.0 倍市盈率进行比较，突显出这只股票在这一基础上看起来被低估。</p>
</div><p><strong>Result: UNDERVALUED</strong></p>
<div class="lb-trans"><p><strong>结果：被低估</strong></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/pe-multiple-vs-industry" alt="" original-src="https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/pe-multiple-vs-industry"/></p>
<p>NYSE:PFE PE Ratio as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 NYSE:PFE 市盈率</p>
</div><p>PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1447 companies where insiders are betting big on explosive growth.</p>
<div class="lb-trans"><p>市盈率讲述了一个故事，但如果真正的机会在其他地方呢？发现 1447 家公司，内部人士正在大举押注于爆炸性增长。</p>
</div><h3>Upgrade Your Decision Making: Choose your Pfizer Narrative</h3>
<div class="lb-trans"><h3>提升你的决策能力：选择你的辉瑞叙事</h3>
</div><p>Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple way to connect your view of Pfizer’s future to concrete numbers like revenue, earnings, margins, and a fair value estimate. A Narrative is the story behind your assumptions, turning ideas about pipelines, patent cliffs, or cost cuts into a structured forecast, and then into a fair value that you can directly compare to today’s share price to inform a decision on whether to buy, hold, or sell. Narratives on Simply Wall St, available to millions of investors through the Community page, are designed to be easy to use, and they update dynamically as new data, news, and earnings are released so your story stays in sync with reality. For example, one Pfizer Narrative might assume a fair value of about $35.77 per share based on stronger margins and a successful obesity and oncology expansion, while a more cautious Narrative might see fair value closer to $24.00, reflecting tougher pricing, slower growth, and execution risks.</p>
<div class="lb-trans"><p>早些时候我们提到，有一种更好的方式来理解估值，因此让我们向你介绍叙事，这是一种将你对辉瑞未来的看法与收入、收益、利润率和公允价值估计等具体数字联系起来的简单方法。叙事是你假设背后的故事，将关于产品线、专利悬崖或成本削减的想法转化为结构化的预测，然后转化为公允价值，你可以直接与今天的股价进行比较，以决定是买入、持有还是卖出。在 Simply Wall St 上的叙事，面向数百万投资者，通过社区页面提供，旨在易于使用，并随着新数据、新闻和收益的发布动态更新，以便你的故事与现实保持同步。例如，一个辉瑞叙事可能假设基于更强的利润率和成功的肥胖及肿瘤扩展，公允价值约为每股 35.77 美元，而一个更谨慎的叙事可能会看到公允价值接近 24.00 美元，反映出更严格的定价、较慢的增长和执行风险。</p>
</div><p>For Pfizer however we will make it really easy for you with previews of two leading Pfizer Narratives:</p>
<div class="lb-trans"><p>然而，对于辉瑞，我们将为你提供两个领先辉瑞叙事的预览：</p>
</div><p><strong>🐂 Pfizer Bull Case</strong></p>
<div class="lb-trans"><p><strong>🐂 辉瑞牛市案例</strong></p>
</div><p>Fair value in this bullish Narrative is estimated at $29.08 per share.</p>
<div class="lb-trans"><p>在这个看涨叙事中，公允价值估计为每股 29.08 美元。</p>
</div><p>At the last close of $25.80, this implies Pfizer is trading at roughly 11.3% below that fair value.</p>
<div class="lb-trans"><p>在最后收盘价为 25.80 美元的情况下，这意味着辉瑞的交易价格大约低于该公允价值 11.3%。</p>
</div><p>Revenue growth in this scenario is modeled at approximately -2.9% a year.</p>
<div class="lb-trans"><p>在这种情况下，收入增长模型约为每年-2.9%。</p>
</div><ul>
<li>Assumes obesity, oncology, and other late stage innovative therapies support a rerating of Pfizer and underpin long term earnings resilience despite patent expirations.</li>
<li>Leans on digitalization, emerging market expansion, and targeted deals to drive margin improvement and diversify away from COVID era volatility.</li>
<li>Aligns broadly with bullish analysts who see sector wide easing of U.S. pricing fears and pipeline execution as catalysts for multiple expansion.</li>
</ul>
<div class="lb-trans"><ul>
<li>假设肥胖症、肿瘤学和其他晚期创新疗法支持辉瑞的重新评级，并在专利到期的情况下支撑长期盈利韧性。</li>
<li>依靠数字化、新兴市场扩张和有针对性的交易来推动利润改善，并减少 COVID 时代的波动性。</li>
<li>与看涨分析师的观点大致一致，他们认为美国整体定价担忧的缓解和管道执行是多重扩张的催化剂。</li>
</ul>
</div><p><strong>🐻 Pfizer Bear Case</strong></p>
<div class="lb-trans"><p><strong>🐻 辉瑞熊市案例</strong></p>
</div><p>Fair value in this more cautious Narrative is set at $24.00 per share.</p>
<div class="lb-trans"><p>在这个更谨慎的叙述中，公允价值定为每股 24.00 美元。</p>
</div><p>With the stock at $25.80, that implies Pfizer is trading about 7.5% above this bearish fair value.</p>
<div class="lb-trans"><p>目前股价为 25.80 美元，这意味着辉瑞的交易价格约高出这一悲观公允价值 7.5%。</p>
</div><p>Revenue growth in this scenario is modeled at around -4.2% a year.</p>
<div class="lb-trans"><p>在这种情况下，收入增长模型约为每年-4.2%。</p>
</div><ul>
<li>Emphasizes global drug price pressure, U.S. policy reforms, and patent cliffs on key products as headwinds that could erode revenue and compress margins.</li>
<li>Questions whether new R&amp;D assets and acquisitions can arrive fast enough, and at sufficient scale, to offset erosion from aging blockbusters.</li>
<li>Views today’s share price as close to fairly valued or slightly rich, with limited upside if pricing reforms and competitive pressures play out at the pessimistic end of expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li>强调全球药品价格压力、美国政策改革和关键产品的专利悬崖是可能侵蚀收入和压缩利润的逆风。</li>
<li>质疑新的研发资产和收购是否能及时到位，并且规模足够大，以抵消老牌畅销药的侵蚀。</li>
<li>认为今天的股价接近公允价值或略显高估，如果定价改革和竞争压力在悲观预期下展开，潜在上行空间有限。</li>
</ul>
</div><p>Do you think there's more to the story for Pfizer? Head over to our Community to see what others are saying!</p>
<div class="lb-trans"><p>你认为辉瑞的故事还有更多内容吗？前往我们的社区看看其他人怎么说！</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/quote-price" alt="" original-src="https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/quote-price"/></p>
<p>NYSE:PFE 1-Year Stock Price Chart</p>
<div class="lb-trans"><p>纽约证券交易所:PFE 1 年股票价格走势图</p>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用于国防和灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的，而是完全自主的塔楼，能够在 30 分钟内提供 5G、ISR 和雷达服务，覆盖任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

Is Pfizer Shifting From Defensive Stock To Value Opportunity After Post Pandemic Restructuring?

- 辉瑞公司股票在过去三年下跌约 42.8%，但近期开始稳定。  
- 该公司正在重塑疫情后的身份，投资非 COVID 产品线以多元化收入。  
- 估值分析显示辉瑞股票被低估，当前市价显著低于其现金生成潜力。  

辉瑞在疫情后重组后是否从防御性股票转变为价值投资机会？